Skip to main content
Premium Trial:

Request an Annual Quote

Spartan Bioscience to Sell Assets to Finance Firm Casa-Dea

NEW YORK — Spartan Bioscience said on Wednesday that it has agreed to sell off its assets to Canadian private investment fund Casa-Dea Finance.

Ottawa, Ontario-based Spartan, founded in 2005, develops molecular diagnostic technologies including its flagship Spartan Cube, a portable PCR-based analyzer that runs tests for COVID-19, Legionnaires' disease-causing Legionella bacteria, and CYP2C19 mutations.

The transaction is expected to close this month. Additional terms were not disclosed.

"We are thrilled to be acquiring Spartan's revolutionary platform, along with retaining many of the organization's devoted employees," Casa-Dea CEO Darrell Edgett said in a statement.

"Casa-Dea's acquisition will represent not only a material affirmation of our technology's potential, but also, an invaluable opportunity to keep our people, and assets, in Canada," Steve Edgett, who has replaced Paul Lem as Spartan's CEO, added in the statement.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.